|
|
|
| Overview on the Antineoplastic Drugs Market |
| LI Min1, WU Ri-wei2 |
1 Institute of Science and Technology Strategy, Jiangxi Academy of Sciences, Nanchang 330096, China;
2 National High-Tech Industrial Development, Nanchang 330096, China |
|
|
|
Abstract Cancer is the highest mortality disease both in developed and in developing countries, and the mortality and incidence rates are increasing persistently. There is a huge market with big potential for antineoplastic drugs. There are 128 kinds of antineoplastic drugs have been approved by FDA until 2015. The global market scale is more than 100 billion US dollars. The targeted drugs are the mainstream, which has holded the proportion of 62%. The market concentration of antineoplastic drugs is very high. Roche is the leader. Many companies showed great enthusiasm in development of antineoplastic drugs. The traditional antineoplastic drugs are the mainstream in domestic market. The market share of targeted drugs is increasing rapidly and the mount of domestic independent development antineoplastic drugs is raising. The domestic market scale is 95.783 billion yuan in 2015 and will be more and more biger in the future.
|
|
Received: 12 September 2016
Published: 25 April 2017
|
|
|
|
|
[1] 陈雪静. 抗肿瘤抗体药物的研究进展. 中国生物制品学杂志, 2015, 28(1):84-90. Chen X J. Advances in research on therapeutic antibodies against tumors. Chinese Journal of Biologicals, 2015, 28(1):84-90.
[2] 于元元, 冯柳, 刘京京, 等. 抗肿瘤药物全球市场分析. 药事管理, 2013, 48(2):155-158. Yu Y Y, Feng L, Liu J J, et al. Global market analysis on antitumor drugs. Chinese Pharmaceutical Journal, 2013, 48(2):155-158.
[3] Kinch M S. An analysis of FDA-approved drugs for oncology. Drug Discover Today, 2014, 19(12):1831-1835.
[4] 胡宏祥, 王学清, 张华, 等. 分子靶向抗肿瘤药物的作用机制及临床研究进展. 药学学报, 2015, 50(10):1232-1239. Hu H X, Wang X Q, Zhang H. et al. Mechanism and clinical progress of molecular targeted cancer therapy. Acta Pharmaceutica Sinica, 2015, 50(10):1232-1239.
[5] 宋洋. 国际抗肿瘤药物市场趋势. 科技信息, 2013, 21:462-463. Song Y. Analysis of international anticancer drug market trends. Science & Technology Information, 2013, 21:462-463.
[6] 熊杏安, 王宗喜. 分子靶向抗肿瘤药物研究进展. 长江大学学报, 2014, 11(21):103-105. Xiong X A, Wang Z X. The study progress of molecular-targeted antitumor drugs. Journal of Yangtze University. 2014, 11(21):103-105.
[7] Dietel M, Johrens K, Laffert M, et al. Predictive molecular pathology and its role in target cancer therpy:a review focussing on clinical relevance. Cancer Gene Therpy, 2013, 20(4):211-221.
[8] 柏静, 杨长福, 黄高, 等. 小分子靶向抗肿瘤药物的研究进展. 肿瘤药学, 2015, 5(3):168-173. Bai J, Yang C F, Huang G, et al. Research progress of small-molecule targeted anti-tumor drugs. Anti-tumor Pharmacy, 2015, 5(3):168-173.
[9] Chen W, Zheng R, Baade P D, et al. Cancer statistics in China. CA:A Cancer Journal for Clinicians, 2016, 66(2):115-132.
[10] 刘姹. 重磅抗癌药市场之中国特色. 医药经济报, 2016, 6月24日,第004版. Liu CH. The Chinese characteristics of the blockbuster cancer drug market. Medicine Economic Report, 2016, 6,24,004.
[11] 于小婷, 韩晟, 张慕禹, 等. 我国医疗机构抗肿瘤药物行业集中度分析. 中国药杂志, 2013, 22(24):2852-2855. Yu X T, Han S, Zhang M Y, et al. Concentration ratio analysis of antineoplastic drugs from medical institutions in China. Chinese Journal of New Drugs, 2013, 22(24):2852-2855.
[12] 吴志. 抗肿瘤药挺进"廉价箱". 科技日报, 2013,5月2日,第005版. Wu Z. Anti-tumor drugs advance into the "cheap box". Science and Technology Daily, 2013,5,2,005.
[13] 田红, 肖桂芝, 刘永贵. 抗肿瘤药物市场分析. 现代药物与临床, 2013, 28(3):424-427. Tian H, Xiao G Z, Liu Y G. Market analysis on antitumor drugs. Drugs & Clinic, 2013, 28(3):424-427. |
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
